




RealRate

PHARMACEUTICAL 2025

VYNE Therapeutics Inc
Rank 67 of 225



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of VYNE Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VYNE Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 119% points. The greatest weakness of VYNE Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 289%, being 75% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	64,437
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,819
Liabilities, Non-Current	0
Other Assets	2,355
Other Compr. Net Income	-6.0
Other Expenses	4.0
Other Liabilities	0
Other Net Income	3,807
Other Revenues	501
Property and Equipment	113
Research and Development	30,946
Selling, General and Administrative Expense	13,192

Output Variable	Value in 1000 USD
Assets	66,905
Liabilities	14,819
Expenses	44,142
Revenues	501
Stockholders Equity	52,086
Net Income	-39,834
Comprehensive Net Income	-39,837
BaseVar	65,090
ECR before Limited Liability	180%
Economic Capital Ratio	289%